Compare F.N.B. Corporation Common Stock (FNB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Tempus AI — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Tempus AI trades at $66.48 (market cap $12.40B). The key difference: Tempus AI is far larger — about 2.1× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Tempus AI for 23 Days on average.
| FNB | TEM | |
|---|---|---|
Market Cap | $6.03B | $12.40B |
Volume | 7,117,178 | 6,036,503 |
Sector | Financials | Broad Market / Factor |
52-Week High | $19.49 | $92.45 |
52-Week Low | $14.65 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $10.52B | $13.03B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
